Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

dy of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive B-cell Non Hodgkin Lymphoma (DLBCL, MCL, FL). The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP. This global, multi-center study, conducted by Janssen, has been fully accrued with 17 patients and an update on the dose escalating phase of this study was provided at ASCO 2013.With a recommended Phase II dose established, the study has enrolled additional 15 patients with newly diagnosed DLBCL and is currently in the expansion phase.
  • DBL3001: Phase III study of ibrutinib in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with newly diagnosed non-germinal center B-cell subtype of DLBCL. This trial is a randomized, multi-center, double-blinded, controlled trial of ibrutinib plus R-CHOP versus R-CHOP in patients with newly diagnosed non-GCB subtype DLBCL. The primary endpoint of the study is to demonstrate a clinically significant improvement in event-free survival when compared to R-CHOP. This global study, conducted by Janssen, is not yet recruiting and Janssen plans to enroll 800 patients worldwide.
  • FL

  • FLR2002: Phase II study of ibrutinib in patients with R/R follicular lymphoma (FL). This is a multi-center, global study of ibrutinib in patients with chemoimmunotherapy-resistant FL, whose disease has relapsed from at least 2 prior lines of therapy, including at least 1 rituximab combination chemotherapy regimen. The primary endpoint of this study is objective response rate. This global study, conducted by Janssen, is recruiting and Janssen plans to enroll 110 patients.
  • WM

  • NCI STUDY: Phase II study of ibrutinib in patients with R/R WM. This is a multicenter, open label study with a primary endpoint of ORR and is currently exploring ibrutinib administration at 420 mg in patients with WM who have failed at least 1 prior thera
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... -- According to a new market research ... Device, Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... reach $56.50 Billion by 2020, growing at a CAGR ... 235 market data Tables and 71 Figures spread through ...
    (Date:9/17/2014)... Sept. 17, 2014  The law firm McElroy, ... that it will serve as host for "Show ... the Risks of Healthcare Reform," a one-day conference ... delivery systems, reimbursement, compliance and enforcement in a ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  ...
    (Date:9/17/2014)... , Sept. 17, 2014   GS1 US ... to implement GS1 Standards to support the 2013 ... patient safety and security in the pharmaceutical supply ... Standards to U.S. Pharmaceutical Supply Chain Business Processes ... , was developed in collaboration with GS1 ...
    Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
    ... Inc. (OTC: HEWA) a leading VIPPS accredited retail mail-order ... ended June 30, 2011. For the ... increased $753,059 to $2,519,721, up 43% compared to the ... in the Company,s prescription business. Prescriptions filled increased from ...
    ... in global nutrition.  Abbott expects to increase its nutrition revenues ... end of 2014. China also continues to be an important part ... the year, more than 26 percent of Abbott,s global sales ... Nutrition,s global sales were in emerging markets. ...
    Cached Medicine Technology:HealthWarehouse.com Reports 43% Revenue Growth Year-Over-Year 2Abbott Expanding Manufacturing Capacity in China to Meet Demands of Fast-Growing Nutrition Market 2
    (Date:9/17/2014)... Prevention is the best treatment for the Enterovirus ... children and teenagers in 12 states, including nearby Oklahoma ... Legacy ER & Urgent Care (LER) in Frisco, Texas. ... EV-D68 so far in North Texas, but with it ... “Implementing prevention strategies now may help keep any outbreak ...
    (Date:9/17/2014)... (PRWEB) September 17, 2014 The Food ... today, September 17, 2014, to consider: , ... Therapy (TRT), and, 2. The potential ... , With the TRT litigation ongoing, an informally-organized litigation ... the dangers of testosterone replacement therapy. Among others, ZKB ...
    (Date:9/17/2014)... (PRWEB) September 17, 2014 A petition ... ) in laparoscopic hysterectomies and other gynecological surgeries has ... to figures posted on Change.org, at least 84,908 supporters ... , According to a recent report from ABC News, ... by Dr. Hooman Noorchashm, after his wife, Dr. Amy ...
    (Date:9/17/2014)... The Delta Dental Community Care Foundation announced today ... Health Foundation: America’s ToothFairy (NCOHF) to support oral health ... Zone Program® in California. , The Orange County NCOHF ... local constituent groups and stakeholders in a comprehensive approach ... its devastating effects on local families. The support of ...
    (Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, ... to explain why antibiotic-resistant bacteria can thrive in a hospital ... to be the culprit. They can easily enter bacteria and ... gene that makes bacteria drug-resistant, a new study finds. ... to a class of antibiotic called carbapenems," said the study,s ...
    Breaking Medicine News(10 mins):Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3
    ... severe injuries on battlefields such as those in Iraq ... of their wounds with multidrug resistant bacteria. The potentially ... Staphylococcus aureus (MRSA), Acinetobacter baumannii , ... . , Dr Clinton K. Murray, from Brooke Army ...
    ... by 43 percent, study found , , SUNDAY, March 29 ... incidence of heart attacks and stroke, the cholesterol-lowering drug ... rate of blood clots in the veins, new research ... presented Sunday at the American College of Cardiology annual ...
    ... caution , , SUNDAY, March 29 (HealthDay News) -- Springtime for ... if they,re not careful, it might also bring a trip ... and lawn mowers alone cause hundreds of thousands of injuries ... Consumer Product Safety Commission. Many of these household accidents are ...
    ... urges first responders to clean equipment regularly with ... -- One in three stethoscopes used by U.S. ... Staphylococcus aureus (MRSA) bacteria, a new study suggests. ... Dentistry of New Jersey swabbed 50 stethoscopes used ...
    ... caregivers, patients and their families joined television stars and ... the third annual National Walk for Epilepsy. Over the ... $2 million dollars and engaged more than 13,000 walkers. ... Money raised from the Walk helps create much needed ...
    ... drug warfarin for many patients, researchers say, , , SATURDAY, ... soon replace the anti-clotting drug warfarin as the first ... a new study suggests. , People with atrial fibrillation ... noted, and typically need to take warfarin for the ...
    Cached Medicine News:Health News:Statin Might Help Fight Blood Clots in Veins 2Health News:Statin Might Help Fight Blood Clots in Veins 3Health News:Tips to Avoid Spring Cleaning Mishaps 2Health News:Third of EMS Stethoscopes Carry MRSA Bacterium 2Health News:Video: Celebrities and Thousands of Walkers Unite at Nation's Capitol to Raise Awareness About Seizures and Epilepsy 2Health News:Video: Celebrities and Thousands of Walkers Unite at Nation's Capitol to Raise Awareness About Seizures and Epilepsy 3Health News:New Device Treats Common Heart Rhythm Disorder 2Health News:New Device Treats Common Heart Rhythm Disorder 3
    ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
    Inquire...
    The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
    ACMI™ Distortion-Free Laparoscopes utilize technical advances in optical lens design to provide images without the fish-eye effect typically found on the peripheral viewing edges of conventional...
    Medicine Products: